Kenneth A. Clark serves as Independent Director of the Company. Mr. Clark has been a member of the law firm Wilson Sonsini Goodrich & Rosati, P.C. since 1993. His practice has focused on strategic transactions in the biopharmaceutical industry for over 25 years. Mr. Clark served on the board of directors of Pharmacyclics, Inc., from November 2012 through the acquisition by AbbVie in May 2015. He holds a B.A. degree from Vanderbilt University and a law degree from the University of Texas at Austin.
As the Independent Director of Pulse Biosciences Inc, the total compensation of Kenneth Clark at Pulse Biosciences Inc is 206,834$. There are 9 executives at Pulse Biosciences Inc getting paid more, with Sandra Gardiner having the highest compensation of 2,097,570$.
Kenneth Clark is 61, he's been the Independent Director of Pulse Biosciences Inc since 2017. There are 2 older and 7 younger executives at Pulse Biosciences Inc. The oldest executive at Pulse Biosciences Inc is Robert Duggan, 75, who is the Independent Chairman of the Board.
Kenneth's mailing address filed with the SEC is C/O SUMMIT THERAPEUTICS INC., 2882 SAND HILL ROAD, SUITE 106, MENLO PARK, CA, 94025.
Over the last 8 years, insiders at Pulse Biosciences Inc have traded over 0$ worth of Pulse Biosciences Inc stock and bought 18,070,761 units worth 194,618,110$ . The most active insiders traders include Robert W Duggan、Mahkam Zanganeh、Manmeet Singh Soni. On average, Pulse Biosciences Inc executives and independent directors trade stock every 52 days with the average trade being worth of 6,179,107$. The most recent stock trade was executed by Burke Thomas Barrett on 20 May 2024, trading 10,000 units of PLSE stock currently worth 85,600$.
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
Pulse Biosciences Inc executives and other stock owners filed with the SEC include: